AI Detection for Cardiovascular Disease Prevention
(AI INFORM Trial)
Trial Summary
What is the purpose of this trial?
AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Nanox.AI Coronary Artery Calcification Assessment for cardiovascular disease prevention?
Research shows that AI-based systems can automatically and accurately measure coronary artery calcium, which is a strong predictor of heart-related events. This automated approach is efficient and correlates well with manual methods, suggesting it could help in early detection and prevention of cardiovascular diseases.12345
Is the AI Detection for Cardiovascular Disease Prevention safe for humans?
How does the AI-based treatment for cardiovascular disease prevention differ from other treatments?
This AI-based treatment is unique because it uses artificial intelligence to automatically detect and quantify coronary artery calcium from CT scans, which helps in assessing the risk of cardiovascular disease more efficiently and accurately compared to traditional methods that rely on manual analysis.125910
Eligibility Criteria
This trial is for individuals aged 40-75 who've had a chest CT scan in the last 3 years and have no history of coronary artery disease, cancer, or any other life-limiting conditions. It's aimed at enhancing cardiovascular disease prevention.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Notification or non-notification of coronary artery calcification detected by AI, followed by recommendation or non-recommendation of preventive therapy
Follow-up
Participants are monitored for changes in LDL-C, initiation or intensification of preventive therapies, and occurrence of cardiovascular events
Treatment Details
Interventions
- Nanox.AI Coronary Artery Calcification Assessment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Nano-X Imaging Limited
Collaborator